Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of C21 on CYP and P-gp Substrates in Healthy Volunteers
NCT05830799Phase 1Completed
- Sponsor
- Vicore Pharma
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), sponsored by Vicore Pharma. Primary endpoints: Maximum Plasma Concentration of Caffeine and Paraxanthine at Day 18, Time to Maximum Plasma Concentration of Caffeine and Paraxanthine at Day 18 and 14 more. Started Mar 2023; status: completed.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05830799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830799.